 |
| |
| Jul-12-18 | Upgrade |
Goldman |
Sell → Neutral |
|
|
| Jun-27-18 | Initiated |
Bernstein |
Mkt Perform |
$129 |
|
| Apr-23-18 | Reiterated |
Citigroup |
Neutral |
$146 → $134 |
|
| Apr-18-18 | Reiterated |
Stifel |
Hold |
$145 → $135 |
|
| Jan-24-18 | Reiterated |
Stifel |
Hold |
$142 → $145 |
|
| Jan-12-18 | Reiterated |
Wells Fargo |
Outperform |
$155 → $160 |
|
| Jan-02-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Oct-18-17 | Reiterated |
Stifel |
Hold |
$140 → $142 |
|
| Oct-18-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$144 → $147 |
|
| Oct-18-17 | Reiterated |
Leerink Partners |
Outperform |
$150 → $165 |
|
| Oct-16-17 | Reiterated |
Jefferies |
Buy |
$157 → $160 |
|
| Oct-11-17 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-09-17 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
| Sep-25-17 | Initiated |
Citigroup |
Neutral |
$140 |
|
| Sep-20-17 | Downgrade |
Goldman |
Neutral → Sell |
$125 → $130 |
|
| Jul-21-17 | Downgrade |
BTIG Research |
Neutral → Sell |
$110 |
|
| Jul-21-17 | Downgrade |
Alembic Global Advisors |
Neutral → Underweight |
|
|
| Jul-20-17 | Resumed |
Credit Suisse |
Outperform |
$148 |
|
| Jul-05-17 | Reiterated |
Morgan Stanley |
Overweight |
$135 → $140 |
|
| May-18-17 | Reiterated |
Stifel |
Hold |
$124 → $128 |
|
|
|
| Aug-17-18 09:34AM | Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication Zacks |
| 04:24AM | Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study Zacks |
| Aug-16-18 02:18PM | HBJ health care panel talks tech innovation, high patient costs American City Business Journals |
| 01:53PM | Trump administration proposes production quota cuts for six opioids Reuters |
| 09:59AM | Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report? Zacks |
| 08:44AM | Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation Motley Fool |
| 07:19AM | Should Gilead Be Worried About This New Monthly HIV Medication? Motley Fool |
| Aug-15-18 05:49PM | Rare Genetic Mutation May Help Drugmakers Battle Obesity Bloomberg Video |
| 12:00PM | A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity Bloomberg |
| Aug-14-18 12:27PM | SurveyMonkey adds Emory dean to board of directors, balancing its gender representation American City Business Journals |
| 06:01AM | Better Buy: AbbVie Inc. vs. Johnson & Johnson Motley Fool |
| Aug-13-18 02:39PM | Jury orders Monsanto to pay $289 million in Roundup cance... CNBC Videos |
| 02:18PM | The Philosophy of Dividend Aristocrat Stocks InvestorPlace |
| 02:12PM | Buy Johnson & Johnson, Now Poised to Rally TheStreet.com |
| 12:36PM | Shire, Shionogi File NDA for Intuniv for Adults in Japan Zacks |
| 08:17AM | 3 Biotech Stocks With Major Catalysts Incoming Motley Fool |
| 07:38AM | The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks |
| Aug-10-18 11:37AM | 3 Reasons Cisco Systems Stock Can Surge to $50 InvestorPlace |
| 08:52AM | Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus Zacks |
| Aug-09-18 05:18PM | Factbox: U.S. companies with exposure to Russia Reuters |
| 02:08PM | Generic Drugmakers Struggle Despite U.S. Push for Copycats Bloomberg |
| Aug-08-18 05:30PM | Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations PR Newswire |
| 02:41PM | NYSE trader: Stocks could drop in August Yahoo Finance Video |
| Aug-07-18 02:04PM | Johnson & Johnson to Participate in the 2018 Wells Fargo 13th Annual Healthcare Conference PR Newswire |
| 01:56PM | Johnson & Johnson to Participate in Barclays Global Consumer Staples Conference PR Newswire |
| 10:26AM | Trump seeks out business leaders as midterm election looms Reuters |
| 09:50AM | Q2 Earnings Drive Pharma ETFs Higher Zacks |
| Aug-06-18 04:07PM | Daabon Strikes Deal With Avicanna, Becoming The Largest Agro Company To Enter The Cannabis Industry Benzinga |
| 02:30PM | 3 Reasons Geron Corporation Stock Could Be a Big Winner Motley Fool |
| 07:28AM | Drug distributor Cardinal's profit beats on pharma unit strength Reuters |
| Aug-05-18 07:42PM | How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs The Wall Street Journal |
| 08:00AM | J&J Bets on Chinese Startup That Uses Llama DNA to Fight Cancer The Wall Street Journal |
| Aug-04-18 12:00PM | The 4 Cheapest 'Dividend Kings' to Buy Today TheStreet.com |
| Aug-02-18 04:13PM | Missouri governments sue drug companies over opioid epidemic American City Business Journals |
| 02:06PM | WHO sees complex vaccine and security questions in Ebola response Reuters |
| 12:35PM | Theravance Biopharma (TBPH) Q2 Loss Narrows, Shares Up Zacks |
| 10:00AM | Cosmetics avoided strict regulation for over a century. Rising health concerns has FDA inquiring. CNBC |
| 06:32AM | Better Buy: Johnson & Johnson vs. Pfizer Motley Fool |
| Aug-01-18 04:48PM | Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down Zacks |
| 04:12PM | Why The 'Heat Wave' For U.S. Pharma Could Continue This Month Investor's Business Daily |
| 03:08PM | NYSE trader: American wealth and stock earnings are at record highs, so I can only be bullish Yahoo Finance Video |
| Jul-31-18 08:58PM | U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict Reuters |
| 07:21PM | U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict Reuters |
| 06:57PM | U.S. insurers grilled on exposure to $4.7 billion J&J talc verdict Reuters |
| 02:27PM | Pfizer CEO expects Trump to eliminate drug rebates Reuters |
| Jul-30-18 07:44PM | [$$] Johnson & Johnson Adds Zarbees Naturals to Bolster Consumer Brands The Wall Street Journal |
| 12:50PM | [$$] Johnson & Johnson Adds Zarbee's Naturals to Bolster Consumer Brands The Wall Street Journal |
| Jul-27-18 06:58PM | All New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 7/27/18) TheStreet.com |
| 03:46PM | NYSE trader: Consumers are slowly retrenching because of trade uncertainty Yahoo Finance Video |
| 11:53AM | Collaborations Help Alkermes Flip to Profitability Motley Fool |
| 02:45AM | Pharma Favorites: 7 Healthy Picks in the Drug Sector Investopedia |
| Jul-26-18 11:46AM | Fight Inflation With Prudent Stock Market Investing InvestorPlace |
| 09:59AM | 5 Dow Jones Stocks That Are Ready to Rise Again InvestorPlace |
| 08:57AM | 3 Stocks That Could Double Your Money Motley Fool |
| Jul-25-18 06:21PM | 3 Great Stocks for Retirees to Own TheStreet.com |
| 01:20PM | Understanding the Components and the Concept of Alpha InvestorPlace |
| 10:51AM | The Top 4 UPS Shareholders (UPS) Investopedia |
| 07:00AM | Did This Top Biotech Stock Just Go on Sale? Motley Fool |
| Jul-24-18 10:56AM | Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings? Zacks |
| 08:37AM | Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK Zacks |
| 08:36AM | The Zacks Analyst Blog Highlights: Johnson & Johnson, Nike, Schlumberger, CSX and Intuitive Surgical Zacks |
| Jul-23-18 03:07PM | Johnson & Johnson Is a Great Company, But Be Patient TheStreet.com |
| 01:30PM | MARKETS: Why Trump is talking down bonds and the dollar, but stocks are just shrugging Yahoo Finance Video |
| 11:09AM | Top Analyst Reports for Johnson & Johnson, Nike & Schlumberger Zacks |
| Jul-22-18 10:47AM | Here's Why Big Pharma Loves This Plan to Lower Drug Prices Motley Fool |
| Jul-20-18 11:16AM | MARKETS: Honeywell stock pops after raising full year guidance Yahoo Finance Video |
| 09:21AM | 3 Stocks That Could Be Added to the Dow Next Motley Fool |
| 08:59AM | Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals Zacks |
| 07:55AM | Dow 30 Stock Roundup: Goldman Sachs, IBM, J&J, Microsoft Earnings Impress Zacks |
| 07:30AM | Three Key Takeaways From Healthcare Earnings Season TheStreet.com |
| Jul-19-18 09:07PM | Women who sued Johnson & Johnson declare victory after $4.69 billion talc verdict Reuters |
| 03:06PM | Women who sued J&J declare victory after $4.69 billion talc verdict Reuters |
| 02:58PM | Johnson & Johnson and General Motors: Growth and Income Stocks Zacks |
| 02:46PM | Women who sued J&J declare victory after $4.69 bln talc verdict Reuters |
| 02:29PM | These 2 Healthcare Giants Had Diverging Short-Term Moves, but Have Parallel Long-Term Stories Motley Fool |
| 01:03PM | Edited Transcript of JNJ earnings conference call or presentation 17-Jul-18 12:30pm GMT Thomson Reuters StreetEvents |
| 10:14AM | AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short' MarketWatch |
| 09:36AM | Should Investors Be Worried About Netflix, United Health, or Johnson & Johnson? Motley Fool |
| 07:34AM | Free Research Report as Johnson & Johnson's Quarterly Earnings Advanced 14.75% ACCESSWIRE |
| Jul-18-18 09:12PM | New Drugs and Expected Growth Could Trigger a Recovery for Celgene Stock InvestorPlace |
| 05:57PM | J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod Zacks |
| 10:05AM | Healthcare ETFs in Focus Following JNJ Q2 Results Zacks |
| 09:56AM | Penn, Johnson & Johnson team up to accelerate innovation American City Business Journals |
| 09:53AM | Stock Market News For Jul 18, 2018 Zacks |
| 09:44AM | Rewind: Why Jim Cramer Is Bullish on Johnson & Johnson Shares TheStreet.com |
| 08:42AM | Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares Benzinga |
| 08:10AM | Today's Research Reports on Stocks to Watch: Johnson & Johnson and Avid Bioservices ACCESSWIRE |
| 03:39AM | J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised) Zacks |
| Jul-17-18 11:41PM | Asian stocks rise as solid US performance lifts spirits Associated Press |
| 10:49PM | [$$] Johnson & Johnsons Pharma Business Fuels Sales Growth The Wall Street Journal |
| 10:13PM | Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch Zacks |
| 09:31PM | What's Behind Johnson & Johnson's Double-Digit Growth? Motley Fool |
| 07:01PM | Jim Cramer: A Pretty Wild Rally In Three Oppositional Groups TheStreet.com |
| 05:37PM | British pharma company Eusa set to unveil deal with giant Johnson & Johnson The Telegraph |
| 05:29PM | What Happened in the Stock Market Today Motley Fool |
| 05:12PM | After the Bell: Dow Rises 56 Points as Stocks Keep Chugging Higher Barrons.com |
| 04:52PM | US companies are shipping goods before they're hit with tariffs: report Fox Business Videos |
| 04:50PM | MedPlast Holdings, Inc. -- Moody's assigns B2 CFR to MedPlast Holdings, Inc. Moody's |
| 04:42PM | Johnson & Johnson climbs while Netflix and UnitedHealth slip Associated Press |
| 04:39PM | US STOCKS-Wall St climbs on Powell comments, earnings Reuters |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Option Exercise | 90.44 | 155,342 | 14,049,130 | 357,906 | Feb 20 07:46 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Sale | 129.86 | 155,342 | 20,172,401 | 202,564 | Feb 20 07:46 PM | | Caruso Dominic J | Exec VP, Finance; CFO | Feb 09 | Option Exercise | 0.00 | 10,601 | 0 | 154,703 | Feb 13 06:54 PM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Feb 09 | Option Exercise | 0.00 | 9,812 | 0 | 78,348 | Feb 13 06:54 PM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 09 | Option Exercise | 0.00 | 5,830 | 0 | 69,992 | Feb 13 06:54 PM | | Gorsky Alex | Chairman, CEO | Feb 09 | Option Exercise | 0.00 | 33,165 | 0 | 285,990 | Feb 13 06:54 PM | | PETERSON SANDRA E | Exec VP, Group WW Chairman | Feb 09 | Option Exercise | 0.00 | 11,445 | 0 | 70,205 | Feb 13 06:54 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 09 | Option Exercise | 0.00 | 13,252 | 0 | 181,655 | Feb 13 06:55 PM | | Ullmann Michael H | Exec VP, General Counsel | Feb 09 | Option Exercise | 0.00 | 5,953 | 0 | 115,257 | Feb 13 06:55 PM | | Kapusta Ronald A | Controller, CAO | Feb 09 | Option Exercise | 0.00 | 2,702 | 0 | 32,666 | Feb 13 06:55 PM | | Mesquita Jorge S. | Exec VP, WW Chair, Consumer | Feb 02 | Option Exercise | 0.00 | 32,688 | 0 | 32,688 | Feb 06 04:21 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Oct 31 | Option Exercise | 0.00 | 75,492 | 0 | 203,142 | Nov 02 05:01 PM |
|
|
|
|
|
|
